Enliven Therapeutics, Inc.
Public company- Headquarters
- BURLINGAME, California
- Ticker
- ELVN
- CIK
- 0001672619
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorKristine Ball | Oct 14, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class II director appointed: Kristine Ball
Kristine Ball was named Class II director of Enliven Therapeutics, Inc., effective October 14, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 14, 2026Role: Class II director
Only one public record so far. We add events as soon as a new filing lands; watch Enliven Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026